VACC reports_updated phase-1b data_for HBV therapeutic vaccine VT300: https://www.globenewswire.com/news-release/2022/06/22/2466880/0/en/Vaccitech-s-VTP-300-induced-sustained-reductions-of-surface-antigen-in-patients-with-chronic-hepatitis-B-both-as-a-monotherapy-and-in-combination-with-a-single-low-dose-of-anti-PD-.html